Nordic Nanovector

Carnegie Investment Bank Norway congratulates Nordic Nanovector ASA on the NOK 250 million private placement completed on 19 January 2022.
 
Nordic Nanovector is targeting the preliminary readout of three-month top line data from its pivotal PARADIGME trial with Betalutin® in H2’2022, a key value inflection point. The proceeds from the private placement are expected to finance the company beyond PARADIGME readout and further an additional three months into 2023 to maximise shareholder value from the PARADIGME clinical trial.
 
Carnegie is proud to have acted as Joint Bookrunner in the private placement, and wishes to thank Chairman Jan Hendrik Egberts, CEO Erik Skullerud, CFO Malene Brondberg and rest of the Nordic Nanovector team for great collaboration and for the vote of confidence.